Durrie Vision

To investigate whether dilute brimonidine (0.025%) reduces patient discomfort, subconjunctival hemorrhage, and injection after LASIK without a significant increase in the rate of flap complications or surgical enhancements. This randomized, double-blind, prospective study enrolled 180 patients (360 eyes) in a contralateral eye comparison of topical dilute brimonidine, naphazoline/pheniramine, or Systane Ultra (Alcon Laboratories, Inc., Fort Worth, TX) administered shortly before LASIK for any indication. Patients were evaluated for subconjunctival hemorrhage, injection, and flap dislocation 1 hour and 1 day postoperatively. Patient questionnaires measuring patient comfort and ocular symptoms were administered at these same follow-up visits. Patients were examined for 3 months to determine similar outcomes for standard indices of safety, predictability, efficacy, and enhancement rates. Scores of patient discomfort, subconjunctival hemorrhage, and injection were significantly lower in eyes treated with dilute brimonidine at the 1 hour and 1 day postoperative examinations. Refloats for mild-flap edge wrinkling were required in 3 brimonidine eyes (2.5%), 1 naphazoline/pheniramine eye (0.8%), and no control eyes, but this difference did not reach statistical significance (P = .18). There was no significant difference between eyes at 3 months in terms of visual acuity, refractive error, corrected distance visual acuity, or rate of enhancement. Use of dilute brimonidine before LASIK reduces subconjunctival hemorrhage and injection and improves patient comfort after surgery. Flap edge wrinkling requiring refloat may still be a complication with dilute brimonidine.

To evaluate the endothelial cell density (ECD) change after laser-assisted in situ keratomileusis (LASIK) using IntraLase FS30® and the influence of anterior chamber gas bubbles (AC gas bubbles) produced during flap creation on the corneal endothelium during the excimer laser ablation. Myopic LASIK was performed in 436 eyes of 252 patients at Shinagawa LASIK Center. Average age was 32.4±7.05 years. IntraLase FS30® was used for flap creation and Allgretto Wave Eye-Q® 400Hz was used for excimer laser ablation. Preoperative and 3-month postoperative ECD were measured with a noncontact specular microscope (Noncon Robo FA-3509®) and compared. The preoperative and 3-month postoperative ECD changes that developed AC gas bubbles during the flap creation (19 eyes of 18 patients) were also examined. The change of ECD was compared to the group that did not produce AC gas bubbles. The average ECD reduction after LASIK was -15±102 cells/mm2 for AC gas bubbles (-) group (0.51%, p>0.05) and -35±130 cells/mm2 (1.21%, p>0.05) for AC gas bubbles (+) group. There was no significant ECD change in the AC gas bubbles (-) and AC gas bubbles (+) groups, and no significant difference was observed between AC gas bubbles (-) and AC gas bubbles (+) groups. IntraLase FS30® is a safe and effective tool for LASIK operation which does not cause damage to corneal endothelium. Anterior chamber gas bubbles produced during flap creation did not damage corneal endothelial cells and did not interfere with LASIK operations.

PurposeTo evaluate the safety of Systane® Lubricant Eye Drops in relieving the symptoms of dry eye following laser-assisted in situ keratomileusis (LASIK) surgery.MethodsThis was a randomized, double-masked, single-center, placebo-controlled, contralateral eye study of 30 patients undergoing LASIK surgery. The mean age of patients was 42.4 ± 10.7 years, and the mean spherical equivalent was −3.29 (range, +1.75 to −7.38). Patients’ right and left eyes were randomized to receive either Systane® or placebo – a preserved, thimerosal-free saline solution – beginning from the day of surgery and ending 30 days following surgery. Outcome measures included tear film break up time (TFBUT), visual acuity, degree of corneal and conjunctival staining, and treatment-related adverse events.ResultsPreoperatively, placebo-treated eyes had statistically significantly higher sum corneal staining score than Systane®-treated eyes (p = 0.0464); however, the difference was clinically insignificant (p = 0.27). Two weeks post operatively, the average TFBUT in the Systane®-treated eyes was 1.23 seconds longer than that of the placebo-treated eyes (p = 0.028). All other evaluated variables were comparable between the two treatments. No adverse events were reported in the study.ConclusionSystane® Lubricant Eye Drops are safe for use following LASIK surgery to relieve the discomfort symptoms of dry eye associated with the procedure.